On October 21, 2025, Amphastar Pharmaceuticals signed a 10-year exclusive distribution agreement with Nanjing Chengong Pharmaceutical to expand their BAQSIMI® nasal powder product in Greater China, with profit-sharing based on sales performance. This agreement is a related party transaction, as key executives hold equity interests in Chengong.